(-)-epigallocatechin 3-gallate multiple interactions ISO RGD:1352457 6480464 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of LGALS3BP mRNA CTD PMID:22079256 1,1-dichloroethene increases expression ISO RGD:734457 6480464 vinylidene chloride results in increased expression of LGALS3BP mRNA CTD PMID:26682919 1,2-dimethylhydrazine multiple interactions ISO RGD:734457 6480464 [1, 2-Dimethylhydrazine co-treated with Folic Acid] results in decreased expression of LGALS3BP mRNA CTD PMID:22206623 17alpha-ethynylestradiol increases expression EXP 6480464 Ethinyl Estradiol results in increased expression of LGALS3BP mRNA CTD PMID:17557909 17beta-estradiol multiple interactions ISO RGD:1352457 6480464 [Estradiol co-treated with Tetrachlorodibenzodioxin] results in increased expression of LGALS3BP mRNA CTD PMID:19619570 17beta-estradiol increases expression EXP 6480464 Estradiol results in increased expression of LGALS3BP mRNA CTD PMID:32145629 , PMID:35192832 17beta-estradiol multiple interactions EXP 6480464 [estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of LGALS3BP mRNA CTD PMID:32741896 17beta-estradiol increases expression ISO RGD:734457 6480464 Estradiol results in increased expression of LGALS3BP mRNA CTD PMID:15289156 , PMID:19484750 17beta-estradiol increases expression ISO RGD:1352457 6480464 Estradiol results in increased expression of LGALS3BP mRNA CTD PMID:19619570 , PMID:21185374 17beta-estradiol decreases expression EXP 6480464 Estradiol results in decreased expression of LGALS3BP mRNA CTD PMID:20068009 17beta-estradiol 3-benzoate multiple interactions EXP 6480464 [estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of LGALS3BP mRNA CTD PMID:32741896 2,2',4,4'-Tetrabromodiphenyl ether affects expression ISO RGD:734457 6480464 2 more ... CTD PMID:30294300 2,2',5,5'-tetrachlorobiphenyl decreases expression EXP 6480464 2 more ... CTD PMID:23829299 2,3,7,8-tetrachlorodibenzodioxine multiple interactions ISO RGD:1352457 6480464 [Estradiol co-treated with Tetrachlorodibenzodioxin] results in increased expression of LGALS3BP mRNA CTD PMID:19619570 2,3,7,8-tetrachlorodibenzodioxine affects expression EXP 6480464 Tetrachlorodibenzodioxin affects the expression of LGALS3BP mRNA CTD PMID:34747641 2,3,7,8-tetrachlorodibenzodioxine decreases expression ISO RGD:734457 6480464 Tetrachlorodibenzodioxin results in decreased expression of LGALS3BP mRNA CTD PMID:33956508 2,3,7,8-tetrachlorodibenzodioxine affects expression ISO RGD:734457 6480464 Tetrachlorodibenzodioxin affects the expression of LGALS3BP mRNA CTD PMID:21570461 2,3,7,8-tetrachlorodibenzodioxine increases expression EXP 6480464 Tetrachlorodibenzodioxin results in increased expression of LGALS3BP mRNA CTD PMID:21215274 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:1352457 6480464 Tetrachlorodibenzodioxin results in increased expression of LGALS3BP mRNA CTD PMID:19619570 3-chloropropane-1,2-diol increases expression EXP 6480464 alpha-Chlorohydrin results in increased expression of LGALS3BP protein CTD PMID:34915118 4,4'-diaminodiphenylmethane increases expression ISO RGD:734457 6480464 4, 4'-diaminodiphenylmethane results in increased expression of LGALS3BP mRNA CTD PMID:18648102 4,4'-sulfonyldiphenol increases expression ISO RGD:734457 6480464 bis(4-hydroxyphenyl)sulfone results in increased expression of LGALS3BP mRNA CTD PMID:30951980 4,4'-sulfonyldiphenol multiple interactions EXP 6480464 [bisphenol A co-treated with bisphenol F co-treated with bis(4-hydroxyphenyl)sulfone] results in increased expression of LGALS3BP mRNA CTD PMID:36041667 4,4'-sulfonyldiphenol increases expression ISO RGD:1352457 6480464 bis(4-hydroxyphenyl)sulfone results in increased expression of LGALS3BP protein CTD PMID:34186270 5-fluorouracil affects response to substance ISO RGD:1352457 6480464 LGALS3BP protein affects the susceptibility to Fluorouracil CTD PMID:16217747 6-propyl-2-thiouracil increases expression EXP 6480464 Propylthiouracil results in increased expression of LGALS3BP mRNA CTD PMID:24780913 6-propyl-2-thiouracil decreases expression EXP 6480464 Propylthiouracil results in decreased expression of LGALS3BP mRNA CTD PMID:36843608 acetamide increases expression EXP 6480464 acetamide results in increased expression of LGALS3BP mRNA CTD PMID:31881176 acrolein multiple interactions ISO RGD:1352457 6480464 [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in increased oxidation of LGALS3BP mRNA, [Air Pollutants results in increased abundance of [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone]] which results in increased oxidation of LGALS3BP mRNA CTD PMID:32699268 acrylamide affects expression EXP 6480464 Acrylamide affects the expression of LGALS3BP mRNA CTD PMID:28959563 acrylamide decreases expression ISO RGD:1352457 6480464 Acrylamide results in decreased expression of LGALS3BP mRNA CTD PMID:32763439 aflatoxin B1 decreases expression ISO RGD:734457 6480464 Aflatoxin B1 results in decreased expression of LGALS3BP mRNA CTD PMID:19770486 aflatoxin B1 decreases expression ISO RGD:1352457 6480464 Aflatoxin B1 results in decreased expression of LGALS3BP mRNA CTD PMID:27153756 aflatoxin B1 increases expression EXP 6480464 Aflatoxin B1 results in increased expression of LGALS3BP mRNA CTD PMID:22484513 more ... all-trans-retinoic acid multiple interactions ISO RGD:1352457 6480464 [Tretinoin co-treated with arsenic trioxide] results in increased expression of LGALS3BP mRNA CTD PMID:15894607 all-trans-retinoic acid increases expression ISO RGD:1352457 6480464 Tretinoin results in increased expression of LGALS3BP mRNA CTD PMID:15894607 more ... alpha-pinene multiple interactions ISO RGD:1352457 6480464 [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in increased oxidation of LGALS3BP mRNA, [Air Pollutants results in increased abundance of [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone]] which results in increased oxidation of LGALS3BP mRNA CTD PMID:32699268 ammonium chloride affects expression EXP 6480464 Ammonium Chloride affects the expression of LGALS3BP mRNA CTD PMID:16483693 antirheumatic drug decreases expression ISO RGD:1352457 6480464 Antirheumatic Agents results in decreased expression of LGALS3BP mRNA CTD PMID:24449571 aristolochic acid A decreases expression ISO RGD:1352457 6480464 aristolochic acid I results in decreased expression of LGALS3BP protein CTD PMID:33212167 arsenous acid increases expression ISO RGD:1352457 6480464 Arsenic Trioxide results in increased expression of LGALS3BP protein CTD PMID:25419056 arsenous acid multiple interactions ISO RGD:1352457 6480464 [Tretinoin co-treated with Arsenic Trioxide] results in increased expression of LGALS3BP mRNA CTD PMID:15894607 atrazine decreases expression ISO RGD:734457 6480464 Atrazine results in decreased expression of LGALS3BP mRNA CTD PMID:27655631 benzo[a]pyrene decreases expression ISO RGD:734457 6480464 Benzo(a)pyrene results in decreased expression of LGALS3BP mRNA CTD PMID:19770486 benzo[a]pyrene increases methylation ISO RGD:1352457 6480464 Benzo(a)pyrene results in increased methylation of LGALS3BP exon, Benzo(a)pyrene results in increased methylation of LGALS3BP promoter CTD PMID:27901495 benzo[a]pyrene increases expression ISO RGD:734457 6480464 Benzo(a)pyrene results in increased expression of LGALS3BP mRNA CTD PMID:23735875 beta-naphthoflavone multiple interactions EXP 6480464 [Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of LGALS3BP mRNA CTD PMID:18164116 bisphenol A increases expression EXP 6480464 bisphenol A results in increased expression of LGALS3BP mRNA CTD PMID:25181051 , PMID:32145629 bisphenol A multiple interactions EXP 6480464 [bisphenol A co-treated with bisphenol F co-treated with bis(4-hydroxyphenyl)sulfone] results in increased expression of LGALS3BP mRNA CTD PMID:36041667 bisphenol A increases expression ISO RGD:734457 6480464 bisphenol A results in increased expression of LGALS3BP mRNA CTD PMID:34585602 bisphenol A decreases expression EXP 6480464 bisphenol A results in decreased expression of LGALS3BP mRNA CTD PMID:34947998 bisphenol A decreases expression ISO RGD:734457 6480464 bisphenol A results in decreased expression of LGALS3BP mRNA CTD PMID:33221593 bisphenol A affects expression ISO RGD:1352457 6480464 bisphenol A affects the expression of LGALS3BP mRNA CTD PMID:30903817 bisphenol A increases expression ISO RGD:1352457 6480464 bisphenol A results in increased expression of LGALS3BP mRNA CTD PMID:29275510 bisphenol A increases methylation ISO RGD:734457 6480464 bisphenol A results in increased methylation of LGALS3BP promoter CTD PMID:27312807 Bisphenol B increases expression ISO RGD:1352457 6480464 bisphenol B results in increased expression of LGALS3BP protein CTD PMID:34186270 bisphenol F increases expression ISO RGD:734457 6480464 bisphenol F results in increased expression of LGALS3BP mRNA CTD PMID:30951980 bisphenol F increases expression ISO RGD:1352457 6480464 bisphenol F results in increased expression of LGALS3BP protein CTD PMID:34186270 bisphenol F multiple interactions EXP 6480464 [bisphenol A co-treated with bisphenol F co-treated with bis(4-hydroxyphenyl)sulfone] results in increased expression of LGALS3BP mRNA CTD PMID:36041667 butan-1-ol multiple interactions ISO RGD:1352457 6480464 [[Gasoline co-treated with 1-Butanol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of LGALS3BP mRNA CTD PMID:29432896 cadmium dichloride increases expression EXP 6480464 Cadmium Chloride results in increased expression of LGALS3BP mRNA CTD PMID:25993096 carbon nanotube increases expression ISO RGD:734457 6480464 Nanotubes more ... CTD PMID:25554681 carnosic acid decreases expression ISO RGD:734457 6480464 salvin results in decreased expression of LGALS3BP protein CTD PMID:35926579 choline multiple interactions ISO RGD:734457 6480464 [Dietary Fats co-treated with Choline deficiency] results in increased expression of LGALS3BP mRNA, PANX1 gene mutant form inhibits the reaction [[Dietary Fats co-treated with Choline deficiency] results in increased expression of LGALS3BP mRNA] CTD PMID:29246445 ciprofibrate increases expression ISO RGD:734457 6480464 ciprofibrate results in increased expression of LGALS3BP mRNA CTD PMID:12771043 cisplatin multiple interactions ISO RGD:1352457 6480464 [Cisplatin co-treated with jinfukang] results in increased expression of LGALS3BP mRNA, [Piroxicam co-treated with Cisplatin] results in decreased expression of LGALS3BP mRNA CTD PMID:21858171 , PMID:27392435 cisplatin increases expression ISO RGD:1352457 6480464 Cisplatin results in increased expression of LGALS3BP mRNA CTD PMID:27392435 cisplatin increases expression ISO RGD:734457 6480464 Cisplatin results in increased expression of LGALS3BP mRNA CTD PMID:21151649 Cuprizon increases expression EXP 6480464 Cuprizone results in increased expression of LGALS3BP mRNA CTD PMID:26577399 , PMID:27523638 cyclosporin A decreases expression ISO RGD:1352457 6480464 Cyclosporine results in decreased expression of LGALS3BP mRNA CTD PMID:20106945 , PMID:25562108 deoxynivalenol decreases expression ISO RGD:1352457 6480464 deoxynivalenol results in decreased expression of LGALS3BP protein CTD PMID:33890134 diarsenic trioxide multiple interactions ISO RGD:1352457 6480464 [Tretinoin co-treated with Arsenic Trioxide] results in increased expression of LGALS3BP mRNA CTD PMID:15894607 diarsenic trioxide increases expression ISO RGD:1352457 6480464 Arsenic Trioxide results in increased expression of LGALS3BP protein CTD PMID:25419056 diethyl maleate decreases expression EXP 6480464 diethyl maleate results in decreased expression of LGALS3BP mRNA CTD PMID:21161181 diethylstilbestrol increases expression ISO RGD:734457 6480464 Diethylstilbestrol results in increased expression of LGALS3BP mRNA CTD PMID:15289156 dioxygen multiple interactions EXP 6480464 [dan-shen root extract co-treated with Andrographis paniculata extract] inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency co-treated with Particulate Matter] results in decreased expression of LGALS3BP mRNA], [Oxygen deficiency co-treated with Blood Glucose deficiency co-treated with Particulate Matter] results in decreased expression of LGALS3BP mRNA CTD PMID:33729688 dorsomorphin multiple interactions ISO RGD:1352457 6480464 [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LGALS3BP mRNA CTD PMID:27188386 doxorubicin decreases expression ISO RGD:1352457 6480464 Doxorubicin results in decreased expression of LGALS3BP mRNA CTD PMID:29803840 endosulfan decreases expression EXP 6480464 Endosulfan results in decreased expression of LGALS3BP mRNA CTD PMID:29391264 enzyme inhibitor multiple interactions ISO RGD:1352457 6480464 [Enzyme Inhibitors results in decreased activity of OGA protein] which results in increased O-linked glycosylation of LGALS3BP protein CTD PMID:23301498 epoxiconazole decreases expression ISO RGD:734457 6480464 epoxiconazole results in decreased expression of LGALS3BP mRNA CTD PMID:35436446 ethanol increases expression ISO RGD:734457 6480464 Ethanol results in increased expression of LGALS3BP mRNA CTD PMID:30319688 fenthion increases expression ISO RGD:734457 6480464 Fenthion results in increased expression of LGALS3BP mRNA CTD PMID:34813904 folic acid decreases expression ISO RGD:734457 6480464 Folic Acid results in decreased expression of LGALS3BP mRNA CTD PMID:25629700 folic acid multiple interactions ISO RGD:734457 6480464 [1, 2-Dimethylhydrazine co-treated with Folic Acid] results in decreased expression of LGALS3BP mRNA CTD PMID:22206623 furan increases expression EXP 6480464 furan results in increased expression of LGALS3BP mRNA CTD PMID:27387713 genistein increases expression ISO RGD:734457 6480464 Genistein results in increased expression of LGALS3BP mRNA CTD PMID:15289156 gentamycin increases expression EXP 6480464 Gentamicins results in increased expression of LGALS3BP mRNA CTD PMID:22061828 glycidol decreases expression EXP 6480464 glycidol results in decreased expression of LGALS3BP mRNA CTD PMID:24395379 ivermectin decreases expression ISO RGD:1352457 6480464 Ivermectin results in decreased expression of LGALS3BP protein CTD PMID:32959892 ketamine increases expression EXP 6480464 Ketamine results in increased expression of LGALS3BP mRNA CTD PMID:20080153 lidocaine increases expression EXP 6480464 Lidocaine results in increased expression of LGALS3BP mRNA CTD PMID:35283115 lipopolysaccharide decreases expression ISO RGD:734457 6480464 Lipopolysaccharides results in decreased expression of LGALS3BP mRNA CTD PMID:21461237 lipopolysaccharide increases expression ISO RGD:1352457 6480464 Lipopolysaccharides results in increased expression of LGALS3BP protein CTD PMID:30501627 lipopolysaccharide increases expression ISO RGD:734457 6480464 Lipopolysaccharides results in increased expression of LGALS3BP mRNA CTD PMID:27339419 methidathion increases expression ISO RGD:734457 6480464 methidathion results in increased expression of LGALS3BP mRNA CTD PMID:34813904 methylphenidate decreases expression ISO RGD:734457 6480464 Methylphenidate results in decreased expression of LGALS3BP mRNA CTD PMID:22470460 microcystin-LR increases expression ISO RGD:734457 6480464 cyanoginosin LR results in increased expression of LGALS3BP mRNA CTD PMID:17654400 N-methyl-4-phenylpyridinium increases expression ISO RGD:1352457 6480464 1-Methyl-4-phenylpyridinium results in increased expression of LGALS3BP mRNA CTD PMID:24810058 N-nitrosodiethylamine increases expression ISO RGD:734457 6480464 Diethylnitrosamine results in increased expression of LGALS3BP mRNA CTD PMID:12771043 N-nitrosodiethylamine increases expression EXP 6480464 Diethylnitrosamine results in increased expression of LGALS3BP mRNA CTD PMID:19638242 N-nitrosodiethylamine multiple interactions EXP 6480464 [Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of LGALS3BP mRNA, [Diethylnitrosamine co-treated with Thioacetamide] results in increased expression of LGALS3BP mRNA CTD PMID:18164116 , PMID:28943392 N-nitrosomorpholine increases expression EXP 6480464 N-nitrosomorpholine results in increased expression of LGALS3BP mRNA CTD PMID:19716841 ozone multiple interactions ISO RGD:1352457 6480464 [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in increased oxidation of LGALS3BP mRNA more ... CTD PMID:32699268 paracetamol affects expression ISO RGD:734457 6480464 Acetaminophen affects the expression of LGALS3BP mRNA CTD PMID:17562736 paracetamol decreases expression EXP 6480464 Acetaminophen results in decreased expression of LGALS3BP mRNA CTD PMID:33387578 paracetamol decreases expression ISO RGD:1352457 6480464 Acetaminophen results in decreased expression of LGALS3BP mRNA CTD PMID:29067470 PCB138 decreases expression EXP 6480464 2 more ... CTD PMID:23829299 pentachlorophenol increases expression ISO RGD:734457 6480464 Pentachlorophenol results in increased expression of LGALS3BP mRNA CTD PMID:23892564 perfluorooctanoic acid decreases expression ISO RGD:1352457 6480464 perfluorooctanoic acid results in decreased expression of LGALS3BP protein CTD PMID:26879310 phenobarbital decreases expression EXP 6480464 Phenobarbital results in decreased expression of LGALS3BP mRNA CTD PMID:19162173 phenylephrine decreases expression EXP 6480464 Phenylephrine results in decreased expression of LGALS3BP mRNA CTD PMID:18158353 pirinixic acid increases expression ISO RGD:734457 6480464 pirinixic acid results in increased expression of LGALS3BP mRNA CTD PMID:23811191 piroxicam multiple interactions ISO RGD:1352457 6480464 [Piroxicam co-treated with Cisplatin] results in decreased expression of LGALS3BP mRNA CTD PMID:21858171 potassium chromate increases expression ISO RGD:1352457 6480464 potassium chromate(VI) results in increased expression of LGALS3BP mRNA CTD PMID:22079256 potassium chromate multiple interactions ISO RGD:1352457 6480464 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of LGALS3BP mRNA CTD PMID:22079256 quercetin decreases expression ISO RGD:1352457 6480464 Quercetin results in decreased expression of LGALS3BP mRNA CTD PMID:15309432 rotenone decreases expression EXP 6480464 Rotenone results in decreased expression of LGALS3BP mRNA CTD PMID:28374803 rotenone increases expression EXP 6480464 Rotenone results in increased expression of LGALS3BP protein CTD PMID:35544339 SB 431542 multiple interactions ISO RGD:1352457 6480464 [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LGALS3BP mRNA CTD PMID:27188386 silicon dioxide affects secretion ISO RGD:1352457 6480464 Silicon Dioxide analog affects the secretion of LGALS3BP protein CTD PMID:25895662 silver atom affects expression ISO RGD:734457 6480464 Silver affects the expression of LGALS3BP mRNA CTD PMID:27131904 silver(0) affects expression ISO RGD:734457 6480464 Silver affects the expression of LGALS3BP mRNA CTD PMID:27131904 sodium arsenite multiple interactions ISO RGD:1352457 6480464 sodium arsenite results in decreased expression of and affects the splicing of LGALS3BP mRNA CTD PMID:25879800 sodium dichromate increases expression EXP 6480464 sodium bichromate results in increased expression of LGALS3BP mRNA CTD PMID:25993096 sodium fluoride decreases expression ISO RGD:734457 6480464 Sodium Fluoride results in decreased expression of LGALS3BP protein CTD PMID:28918527 Soman increases expression EXP 6480464 Soman results in increased expression of LGALS3BP mRNA CTD PMID:19281266 sulindac multiple interactions ISO RGD:1352457 6480464 Sulindac inhibits the reaction [CDKN1A protein results in increased expression of LGALS3BP mRNA] CTD PMID:15190207 sunitinib decreases expression ISO RGD:1352457 6480464 Sunitinib results in decreased expression of LGALS3BP mRNA CTD PMID:31533062 tamoxifen increases expression ISO RGD:1352457 6480464 Tamoxifen results in increased expression of LGALS3BP mRNA CTD PMID:19155303 tamoxifen affects expression ISO RGD:734457 6480464 Tamoxifen affects the expression of LGALS3BP mRNA CTD PMID:20937368 temozolomide increases expression ISO RGD:1352457 6480464 Temozolomide results in increased expression of LGALS3BP mRNA CTD PMID:31758290 tert-butyl hydroperoxide increases expression ISO RGD:734457 6480464 tert-Butylhydroperoxide results in increased expression of LGALS3BP mRNA CTD PMID:14729362 testosterone multiple interactions EXP 6480464 [estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of LGALS3BP mRNA CTD PMID:32741896 tetrachloromethane decreases expression EXP 6480464 Carbon Tetrachloride results in decreased expression of LGALS3BP mRNA CTD PMID:16239168 tetrachloromethane increases expression ISO RGD:734457 6480464 Carbon Tetrachloride results in increased expression of LGALS3BP mRNA CTD PMID:31919559 thimerosal decreases expression ISO RGD:1352457 6480464 Thimerosal results in decreased expression of LGALS3BP mRNA CTD PMID:27188386 thioacetamide multiple interactions EXP 6480464 [Diethylnitrosamine co-treated with Thioacetamide] results in increased expression of LGALS3BP mRNA CTD PMID:28943392 thioacetamide increases expression EXP 6480464 Thioacetamide results in increased expression of LGALS3BP mRNA CTD PMID:34492290 titanium dioxide increases expression ISO RGD:734457 6480464 titanium dioxide results in increased expression of LGALS3BP mRNA CTD PMID:23557971 , PMID:27760801 triclosan increases expression ISO RGD:1352457 6480464 Triclosan results in increased expression of LGALS3BP mRNA CTD PMID:30510588 triptonide increases expression ISO RGD:734457 6480464 triptonide results in increased expression of LGALS3BP mRNA CTD PMID:33045310 tunicamycin decreases expression ISO RGD:1352457 6480464 Tunicamycin results in decreased expression of LGALS3BP mRNA CTD PMID:22378314 valproic acid affects expression ISO RGD:734457 6480464 Valproic Acid affects the expression of LGALS3BP mRNA CTD PMID:17292431 valproic acid multiple interactions ISO RGD:1352457 6480464 [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LGALS3BP mRNA CTD PMID:27188386 valproic acid decreases expression ISO RGD:1352457 6480464 Valproic Acid results in decreased expression of LGALS3BP mRNA CTD PMID:23179753 more ... valproic acid affects expression ISO RGD:1352457 6480464 Valproic Acid affects the expression of LGALS3BP mRNA CTD PMID:25979313 valproic acid increases methylation ISO RGD:1352457 6480464 Valproic Acid results in increased methylation of LGALS3BP gene CTD PMID:29154799 vancomycin decreases expression ISO RGD:734457 6480464 Vancomycin results in decreased expression of LGALS3BP mRNA CTD PMID:18930951 vinclozolin increases expression EXP 6480464 vinclozolin results in increased expression of LGALS3BP mRNA CTD PMID:22570695 vinclozolin affects expression EXP 6480464 vinclozolin affects the expression of LGALS3BP mRNA CTD PMID:19015723 vorinostat decreases expression ISO RGD:1352457 6480464 vorinostat results in decreased expression of LGALS3BP mRNA CTD PMID:27188386
